Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citalopram + chlordiazepoxide is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reuptake into presynaptic cells, thereby improving mood and alleviating symptoms of depression and anxiety[2][10]. Chlordiazepoxide is a benzodiazepine that acts as an agonist at the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing GABAergic inhibition in the central nervous system to produce anxiolytic, sedative, anticonvulsant, and muscle relaxant effects[3][4][8]. This combination would theoretically provide both antidepressant and anxiolytic benefits. However, there are no widely recognized or marketed fixed-dose products containing both citalopram and chlordiazepoxide; their co-administration may be considered off-label for patients requiring both antidepressant and anxiolytic therapy. Caution is advised due to potential additive central nervous system depressant effects when these drugs are used together[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + chlordiazepoxide.